Jack Cook

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1777978/publications.pdf

Version: 2024-02-01

840119 887659 18 304 11 17 h-index citations g-index papers 23 23 23 368 all docs docs citations times ranked citing authors

#	Article	lF	Citations
1	Application of the Biopharmaceutical Classification System in Clinical Drug Development—An Industrial View. AAPS Journal, 2008, 10, 306-310.	2.2	73
2	A proposal for scientific framework enabling specific population drug dosing recommendations. Journal of Clinical Pharmacology, 2015, 55, 1073-1078.	1.0	39
3	Drug Dosing Recommendations for All Patients: A Roadmap for Change. Clinical Pharmacology and Therapeutics, 2021, 109, 65-72.	2.3	32
4	Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVIDâ€19 Infection. Clinical Pharmacology and Therapeutics, 2020, 108, 1135-1149.	2.3	25
5	Quality-by-Design: Are We There Yet?. AAPS PharmSciTech, 2014, 15, 140-148.	1.5	23
6	Roadmap to 2030 for Drug Evaluation in Older Adults. Clinical Pharmacology and Therapeutics, 2022, 112, 210-223.	2.3	19
7	Industrial Perspective on the Benefits Realized From the FDA's Modelâ€Informed Drug Development Paired Meeting Pilot Program. Clinical Pharmacology and Therapeutics, 2021, 110, 1172-1175.	2.3	15
8	Clinical Relevance of Hepatic and Renal Pâ€gp/ <scp>BCRP</scp> Inhibition of Drugs: An International Transporter Consortium Perspective. Clinical Pharmacology and Therapeutics, 2022, 112, 573-592.	2.3	15
9	A randomized, openâ€label 3â€way crossover study to investigate the relative bioavailability and bioequivalence of crushed sildenafil 20 mg tablets mixed with apple sauce, extemporaneously prepared suspension (EP), and intact sildenafil 20 mg tablets in healthy volunteers under fasting conditions. Clinical Pharmacology in Drug Development, 2015, 4, 74-80.	0.8	14
10	ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ Consortium. Molecular Pharmaceutics, 2020, 17, 361-372.	2.3	13
11	Utility of Model-Based Approaches for Informing Dosing Recommendations in Specific Populations: Report From the Public AAPS Workshop. Journal of Clinical Pharmacology, 2017, 57, 105-109.	1.0	12
12	A Realâ€World Evidence Framework for Optimizing Dosing in All Patients With COVIDâ€19. Clinical Pharmacology and Therapeutics, 2020, 108, 921-923.	2.3	8
13	A Randomized, Open-Label, 3-Way Crossover Study to Demonstrate Bioequivalence of Sildenafil Powder for Oral Suspension With Tablets Used Commercially and in Clinical Studies for the Treatment of Pulmonary Arterial Hypertension. Clinical Pharmacology in Drug Development, 2012, 1, 152-157.	0.8	4
14	Impact of Discordance Among Regulations for Biopharmaceutics Classification System-Based Waivers of Clinical Bioequivalence Studies. Dissolution Technologies, 2015, 22, 6-10.	0.2	3
15	To blind or not to blind first in human and exploratory clinical trials: Acceleration of development vs. risk of bias. Clinical and Translational Science, 2021, , .	1.5	3
16	Regarding Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012–2018. Clinical Pharmacology and Therapeutics, 2021, 109, 1181-1181.	2.3	2
17	The Weight of Evidence From Electrophysiology, Observational, and Cardiovascular End Point Studies Demonstrates the Safety of Azithromycin. Clinical and Translational Science, 2021, 14, 106-112.	1.5	2
18	Response to "Personalized Dosing = Approved Wide Dose Ranges + Dose Titration― Clinical Pharmacology and Therapeutics, 2021, 109, 568-568.	2.3	0